Vital Therapies (NASDAQ:VTL)‘s stock had its “buy” rating restated by equities researchers at William Blair in a research report issued on Sunday.
A number of other brokerages have also commented on VTL. BTIG Research reiterated a “hold” rating on shares of Vital Therapies in a research report on Thursday. BidaskClub upgraded Vital Therapies from a “buy” rating to a “strong-buy” rating in a research report on Thursday, July 12th. ValuEngine upgraded Vital Therapies from a “hold” rating to a “buy” rating in a research report on Friday, June 29th. Finally, Zacks Investment Research upgraded Vital Therapies from a “sell” rating to a “hold” rating in a research report on Saturday, May 12th. Two research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Buy”.
Vital Therapies traded up $0.20, reaching $9.40, during mid-day trading on Friday, according to Marketbeat Ratings. The stock had a trading volume of 261,482 shares, compared to its average volume of 265,913. The firm has a market capitalization of $389.80 million, a price-to-earnings ratio of -7.18 and a beta of 4.21. Vital Therapies has a 52 week low of $2.60 and a 52 week high of $9.75.
Vital Therapies (NASDAQ:VTL) last announced its quarterly earnings data on Tuesday, August 7th. The company reported ($0.30) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.33) by $0.03. equities analysts forecast that Vital Therapies will post -1.13 earnings per share for the current fiscal year.
Large investors have recently bought and sold shares of the company. Northern Trust Corp boosted its position in shares of Vital Therapies by 12.0% in the 1st quarter. Northern Trust Corp now owns 83,688 shares of the company’s stock worth $569,000 after purchasing an additional 8,993 shares during the last quarter. Millennium Management LLC boosted its position in shares of Vital Therapies by 65.6% in the 1st quarter. Millennium Management LLC now owns 414,540 shares of the company’s stock worth $2,819,000 after purchasing an additional 164,175 shares during the last quarter. BlackRock Inc. boosted its position in shares of Vital Therapies by 136.2% in the 4th quarter. BlackRock Inc. now owns 990,828 shares of the company’s stock worth $5,896,000 after purchasing an additional 571,418 shares during the last quarter. Artal Group S.A. boosted its position in shares of Vital Therapies by 14.3% in the 1st quarter. Artal Group S.A. now owns 1,000,000 shares of the company’s stock worth $6,800,000 after purchasing an additional 125,000 shares during the last quarter. Finally, Tibra Equities Europe Ltd bought a new position in shares of Vital Therapies in the 1st quarter worth $416,000. Institutional investors and hedge funds own 28.06% of the company’s stock.
About Vital Therapies
Vital Therapies, Inc, a biotherapeutic company, focuses on developing and commercializing a cell-based therapy for the treatment of acute forms of liver failure in the United States. Its product candidate is the ELAD system, an extracorporeal human allogeneic cellular liver therapy that is in Phase III clinical trials helps in enhancing the rates of survival in patients with acute forms of liver failure.
Further Reading: Trading Penny Stocks
Receive News & Ratings for Vital Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies and related companies with MarketBeat.com's FREE daily email newsletter.